This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.
This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic
Imlygic (talimogene laherparepvec) was turned down by NICE in earlier guidance, with the agency arguing that it could not justify its use because of uncertainty about the therapy's effects on
A product in a new class of cancer therapies that harness the cell-killing power of viruses also debuted in 2015 in the form of Amgen's Imlygic (talimogene laherparepvec), the ... Switzerland. talimogene laherparepvec. Imlygic. malignant melanoma.
review in Europe, as well as oncolytic virus therapy Imlygic (talimogene laherparepvec), approved in the US in October.
Imlygic (talimogene laherparepvec or T-Vec) is a genetically modified live Herpes simplex virus that is designed to infect and destroy melanoma lesions in the skin and lymph nodes that cannot
Amgen's Imlygic (talimogene laherparepvec) is seeking an indication for the treatment of adults with unresectable melanoma that is regionally or distantly metastic (stage IIIB, IIIC and IVM1a).
More from news
Approximately 4 fully matching, plus 16 partially matching documents found.